IDEXX Expands Cancer Dx Panel to Detect Canine Mast Cell Tumors

Reuters01-15
IDEXX Expands Cancer Dx Panel to Detect Canine Mast Cell Tumors

IDEXX Laboratories Inc. has announced advancements in veterinary cancer diagnostics, including the expansion of its IDEXX Cancer Dx Panel to detect canine mast cell tumors, expected to launch in North America in mid-2026. The Cancer Dx Panel, already in use by over 5,500 practices for early lymphoma detection, will now include mast cell tumor detection at no additional cost. Results will be available within 2-3 days. Scientific research on early detection of lymphoma using the IDEXX Cancer Dx test was presented at the Veterinary Cancer Society Annual Conference in September 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IDEXX Laboratories Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260115425467) on January 15, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment